Posted by Michael Wonder on 23 May 2023
Grünenthal's resiniferatoxin receives breakthrough therapy designation from US FDA for pain associated with osteoarthritis of the knee
22 May 2023 - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis.
Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin, currently undergoing clinical Phase III development, received breakthrough therapy designation from the US FDA for pain associated with osteoarthritis of the knee.
